Educational Symposium
Expanding Therapeutic Horizons in IgAN
November 07, 2025 | 12:45 PM - 01:45 PM
Location: Lanier Grand Ballroom G, Hilton Americas-Houston
Session Description
Recent advances in the understanding of IgAN pathophysiology have led to the development of targeted therapies approved by the US Food and Drug Administration and the European Medicines Agency, offering new hope for improved patient outcomes. This symposium provides an in-depth review of emerging treatments, particularly those focused on B cell modulation, and explores the roles of a proliferation-inducing ligand (APRIL) and B cell activating factor (BAFF) in IgAN pathogenesis. Experts highlight how dysregulation of these cytokines drives aberrant IgA production and disease progression, and how therapies targeting them may alter the disease course and improve long-term kidney outcomes. Participants gain valuable insights into the efficacy, safety, and clinical integration of these novel therapies within the evolving IgAN treatment landscape.
Support is provided by educational grants from Otsuka America Pharmaceutical, Inc. and Vera Therapeutics, Inc.
Learning Objective(s)
- Describe the latest guidelines for diagnosing and managing IgAN
- Explain how dysregulation of APRIL and BAFF contributes to disease progression and the rationale for targeting these pathways in emerging therapies
- Discuss current and ongoing clinical trials investigating novel immunomodulatory agents, their therapeutic potential, and implications for personalized patient care
Learning Pathway(s)
- Glomerular Diseases
Moderator
Presentations
- Introduction
12:45 PM - 12:55 PM
- Emerging Insights in the Diagnosis and Care of Patients with IgAN
12:55 PM - 01:15 PM
- Targeting APRIL and BAFF: A New Frontier in IgAN Therapy
01:15 PM - 01:35 PM
- Q&A
01:35 PM - 01:45 PM